Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc. > See! I told you so...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(559)
•••
Comment by chrispion Dec 16, 2021 12:14pm
146 Views
Post# 34237269

RE:See! I told you so...

RE:See! I told you so...I agree JD.
Best news I heard is that as of today, NY-based investment bank Ladenburg Thalmann has been engaged to assist the Board and management evaluate strategic alternatives, including potential M&A. Ladenburg is a level 2 investment bank (level 1 being JP Morgan, Morgan Stanley, and Goldman Sachs) so they've partnered with a very heavy hitter!

Other great news is that Dr. Mario Saltarelli is now Chief Medical Officer at Bioasis and this shows his increasing involvement in getting things done. He is very well respected and known in the Pharma world!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities